Man utd shock win Al-Ola A Abdallah MD (USMIRC) , good tidings finally to beat the blues

Don’t miss our #CME meeting tonight at 6:30 PM CDT at the Hilton Chicago! Expert faculty and education‼️ See you 🫵 tonight! bit.ly/T2024Bispecifi… #ASCO24

In a matching-adjusted indirect comparison, linvoseltamab elicited efficacy outcomes equivalent to those seen with teclistamab-cqyv in triple-class–exposed, R/R multiple myeloma, according to findings . The Tisch Cancer Institute #oncology #medtwitter #ASCO24 onclive.com/view/linvoselt…

We are deeply saddened to report the passing of Dr. Bhuvaneswari Ramaswamy, a renowned and beloved The James breast medical oncologist and researcher who greatly enriched our cancer program before succumbing to breast cancer following a heroic battle.go.osu.edu/bhuvana

Very Excited for City of Hope to be ranked a top 5 cancer hospital #BestHospitals health.usnews.com/best-hospitals…

Learn how off-the-shelf #bispecifics are transforming #Lymphoma and #MultipleMyeloma management in this recording from #ASCO2024, featuring Sundar Jagannath, Sabarish Ayyappan, (Sabarish Ayyappan MD), and Jennifer Crombie (Jennifer Crombie, MD) bit.ly/4aX8rDK

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma - Annals of Oncology annalsofoncology.org/article/S0923-…

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

With durable response rates and positive QOL outcomes, odronextamab could transform therapeutic approaches for these challenging lymphomas, especially for patients with limited options. #lymsm | Benoit T City of Hope Sabarish Ayyappan MD targetedonc.com/view/does-odro…

Very disappointing display @abdallah81md @ manutd

Impressive fightback by our lads Manchester United Al-Ola A Abdallah MD (USMIRC) Saurabh Zanwar

This is true fergie time Manchester United Al-Ola A Abdallah MD (USMIRC) Saurabh Zanwar Gaurang Goswami

We recently published a review on Economics and cost effectiveness of drugs in Multiple myeloma. This is important if we want to reduce disparities and global access. Open access paper- rdcu.be/d6QjP Praneeth Reddy Keesari Charan Thej Reddy Vegivinti

linkedin.com/posts/sabarish… AJMC City of Hope

Cub Paw winners of the week! Great work friends!

We need a better team to match this endeavor ⁦Al-Ola A Abdallah MD (USMIRC)⁩ ⁦Saurabh Zanwar⁩ ⁦Manchester United⁩

Incredibly proud of this groundbreaking CAR-T therapy research from Hasmukh Jain Manju Sengar Rahul Purwar Gaurav Narula MD and others at Tata Memorial Hospital ACTREC-TMC IIT Bombay that demonstrates what the outcomes can be when meaningful collaborations happen thelancet.com/journals/lanha…

We are near and have good speakers...

If you are in LA and please join us to raise funds for myeloma research. The contribution to research always improves quality of people's lives in the future and discovers new therapies. My personal goals are to CURE MM and mitigate side effects of treatments. Let's walk towards

Robert Z. Orlowski Thx for highlighting Dr. Orlowski. Seems to be dose intensity related and stopping the drug reverses it